News
Spectrum Pharmaceuticals(TM) to Present at the Cowen & Company 28th Annual Health Care Conference
IRVINE, Calif.-(Business Wire)-March 14, 2008 - Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), announced today that it will present an overview of the Company on Monday, March 17, 2008 at 11:30 a.m. Eastern Time/8:30 a.m. Pacific, at the Cowen & Company 28th Annual Health Care Conference, being held at The Boston Marriott Copley Place Hotel.
The live webcast of Spectrum's presentation will be available at http://www.spectrumpharm.com. Replays will be available for 30 days.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is focused on building a diversified portfolio of promising late stage drugs, and advancing them through clinical development, regulatory process and commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
Search Our News Using Google Search
Can't find what you want? Try using Google:
